Skip to main content
25 search results for:

Alogliptin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-03-2018 | Alogliptin | News | Article

    Support for alogliptin as add-on therapy for type 2 diabetes

    Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

  2. 12-20-2017 | Specific populations | Review | Article

    Ethnic differences in efficacy and safety of alogliptin: A systematic review and meta-analysis

    Alogliptin is a highly selective, potent, and orally available dipeptidyl peptidase-4 (DPP-4) inhibitor.

  3. 06-28-2017 | Topic page

    Alogliptin_Metformin

  4. 06-28-2017 | Topic page

    Alogliptin_Pioglitazone

  5. 08-16-2018 | DPP-4 inhibitors | Review | Article

    Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

    Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

  6. 09-21-2016 | Heart failure | Article

    Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes

    Fitchett DH, Udell JA, Inzucchi SE. Eur J Heart Fail  2017; 19: 43–53. doi: 10.1002/ejhf.633

  7. 04-17-2018 | DPP-4 inhibitors | At a glance | Article
    Updated July 2019

    Round-up of the DPP-4 inhibitor CV outcome trials

    This occurred in 11.3% of patients taking alogliptin and 11.8% of those assigned to placebo during a median 18 months of follow-up, giving a hazard ratio of 0.96, which was within the prespecified margin of 1.3 for the noninferiority of alogliptin to placebo.

  8. 09-28-2016 | Pancreatitis | News | Article
    News in brief

    Pancreatitis risk small but real with gliptin treatment

    Type 2 diabetes, pancreatitis, gliptin, saxagliptin, alogliptin, sitagliptin, SAVOR-TIMI 53, EXAMINE, TECOS

  9. 05-22-2019 | Sulfonylureas | Editorial | Article

    The CAROLINA trial: Make or break for sulfonylureas?

    Cardio-renal benefit and safety Linagliptin, sitagliptin, and alogliptin have proven cardiovascular safety; however, saxagliptin is associated with an increased risk of hospitalization for heart failure.

  10. 06-21-2018 | Hypoglycemia | Review | Article

    Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

    Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

  11. 06-12-2018 | Empagliflozin | Article

    Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

    Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

  12. 06-08-2018 | Heart failure | News | Article
    News in brief

    Established biomarker predicts HF in type 2 diabetes

    Being randomized to receive alogliptin did not significantly influence their NT-proBNP levels.

  13. 06-05-2018 | Cardiovascular outcomes | Review | Article

    Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

    Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

  14. 06-01-2018 | DPP-4 inhibitors | Article

    Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

    Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

  15. 05-30-2018 | Cardiovascular outcomes | Article

    Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial

    Jarolim P et al. Diabetes Care 2018. doi: 10.2337/dc18-0109

  16. 04-28-2018 | Heart failure | Review | Article

    SGLT2 inhibition and heart failure: Current concepts

    Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

  17. 11-22-2017 | Cardiovascular disorders | Editorial | Article

    Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

    In the EXAMINE trial, the effect of alogliptin was assessed in patients up to 90 days post-ACS [9].

  18. 11-02-2017 | Heart failure | Review | Article

    Treating disease mechanisms in patients with heart failure and diabetes mellitus

    Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

  19. 10-25-2017 | DPP-4 inhibitors | News | Article

    Metformin may moderate DDP-4 inhibitor effect on cardiovascular outcomes

    Matthew Crowley (Duke University School of Medicine, Durham, North Carolina, USA) and colleagues analysed data from three multinational trials examining the effects of the DPP-4 inhibitors sitagliptin, alogliptin, or saxagliptin versus placebo on cardiovascular outcomes in patients with type 2 diabetes.

  20. 10-23-2017 | Cardiovascular disorders | Review | Article

    Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

    Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.